Small risk of severe acute pancreatitis with weight-loss jabs, MHRA says
Agency updates guidance after increase in reports of condition to the yellow card schemePatients on weight-loss jabs should be aware there is a small risk of developing severe acute pancreatitis, the medicines regulator has said.About 1.6 million adults in England, Wales and Scotland used GLP-1...
<p>Agency updates guidance after increase in reports of condition to the yellow card scheme</p><p>Patients on weight-loss jabs should be aware there is a small risk of developing severe acute pancreatitis, the medicines regulator has said.</p><p>About <a href="https://www.ucl.ac.uk/news/2026/jan/16-million-uk-adults-used-weight-loss-drugs-past-year">1.6 million adults</a> in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight, according to recent research.</p> <a href="https://www.theguardian.com/science/2026/jan/29/small-risk-severe-acute-pancreatitis-weight-loss-jabs-mhra">Continue reading...</a>
Read the full article at:
The Guardian World →